COMMUNIQUÉS West-GlobeNewswire

-
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
10/06/2025 -
HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration
10/06/2025 -
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
10/06/2025 -
Dogecoin Cash Inc. (OTCQB: CBDS) Announces Symbol Change to DOGP, Planting Its Flag in the Memeosphere
10/06/2025 -
Virbac : Declaration of the number of share and voting rights 05/2025
10/06/2025 -
Virbac : Déclaration d'actions et de droits de vote 05/2025
10/06/2025 -
Trading by management and close relations of management
10/06/2025 -
Company Update
10/06/2025 -
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
10/06/2025 -
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
10/06/2025 -
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
10/06/2025 -
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
10/06/2025 -
Sanofi: Information concerning the total number of voting rights and shares - May 2025
09/06/2025 -
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2025
09/06/2025 -
Senti Biosciences Announces New Employment Inducement Grants
09/06/2025 -
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
09/06/2025 -
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
09/06/2025 -
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"
09/06/2025 -
Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
09/06/2025
Pages